Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Group USCSW. United States Cancer Statistics: 2001 Incidence and Mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2004.
2. Price B, Ware A: Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004, 159:107–112.
3. Pass HI, Vogelzang N, Hahn S, Carbone M: Malignant pleural mesothelioma. Curr Probl Cancer 2004, 28:93–174. A comprehensive review of the results of trials of different modalities that have been tested in treatment for MPM, as well as sections on pathogenesis, diagnosis, and staging.
4. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999, 68:1799–1804.
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54–63.